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Introduction
CS-1036 ((2R,3R,4R)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-3-yl
4-O-(6-deoxy-β-D-glucopyranosyl)-α-D-glucopyranoside, shown in Fig. 1 , inhibits both salivary and pancreatic α -amylase in the gastrointestinal tract and therefore blocks starch digestion, and as a consequence depresses glucose absorption (Honda et al., 2013) .
Alpha-amylase is responsible for the starch digestion in digestive tracts. Salivary and pancreatic amylases, which exhibits high homologies in humans (>95%, AMY1:
NP_004029, AMY2A: NP_000690 and AMY2B: NP_066188), are known as subtypes for α -amylase (Gumucio et al., 1988; Mashige et al., 1989) . Serum amylase is known as a biomarker for the pancreatic function (Ranson, 1997) , and both amylases are almost equally secreted into human plasma. The docking study using a pancreatic amylase X-ray crystal structure inferred that the pyrrolidine ring of CS-1036 interacted with the active center, and the disaccharide on the other side of CS-1036 bound to the starch binding site of pancreatic amylase (data not shown).
CS-1036 was mainly excreted into urine from systemic circulation, and exhibited the biphasic elimination profiles with relatively long t 1/2 (18.4-30.0 hours at DMD #54452 6 plasma protein binding plays an important role in the CL R (Rowland and Tozer, 2011) .
Serum albumin, which is a major target of the plasma protein binding of drugs, is generally more abundant (520-750 μ M, molecular weight: 67,000) than drug concentration, and therefore, the protein binding of most of the drugs which bind to albumin is constant in the therapeutic concentration range (Wright et al., 1996; Rowland and Tozer, 2011) . At high drug concentrations in the plasma or in the presence of competitors, a saturation of plasma protein binding to serum albumin occurs, and two binding sites with different binding affinity in albumin are occasionally attributed to the concentration-dependent binding (Urien et al., 1981; Stoeckel and Koup, 1984; Roberts et al., 2011) . The other well-known drug binding plasma protein is α 1 -acid glycoprotein (AGP), and some drugs show a nonlinear plasma protein binding due to the limited binding capacity to AGP (9-24 μ M, molecular weight: 42,000) (Wright et al., 1996; Fuse et al., 1999; Fuse et al., 2000) .
To clarify the causes for long t 1/2 , the plasma protein binding of CS-1036 in rats and monkeys was evaluated by ultrafiltration, and the pharmacokinetics (PK) and plasma protein binding of CS-1036 in humans were also investigated to evaluate the species difference in the elimination phase. Furthermore, the target binding protein of CS-1036 in plasma was identified, and the relationship between the plasma protein binding and the in vivo elimination of CS-1036 was investigated.
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Materials and Methods
Materials.
CS-1036 and its internal standard substance, R-187454 ( 2 H 5 form of CS-1036),
were synthesized at Daiichi Sankyo Co., Ltd. Amylase antibody (MAK <H-S-AMY> M-Tu66C7-IgG) was purchased from Roche Diagnostics GmbH (Mannheim, Germany).
The control antibody (IgG from murine serum), albumin from rat serum, albumin from human serum, amylase from human saliva and amylase from human pancreas were purchased form Sigma-Aldrich Co. (St. Louis, MO, USA) Other reagents and solvents used were commercially available and either of guaranteed, high-performance liquid chromatography or liquid chromatography-mass spectrometry grade.
Animals.
All animal experimental procedures were performed in accordance with the institutional animal care guidelines of Daiichi Sankyo Co., Ltd. Male F344/DuCrlCrlj (F344) rats at 7 weeks of age and male Sprague-Dawley (Crl:CD(SD)) rats at 8 weeks of age were purchased from Charles River Laboratories Japan, Inc. (Yokohama, Kanagawa, Japan) and then used after an acclimatization period of 5-8 days. Male cynomolgus monkeys at 3-5 years of age were purchased from CLEA Japan, Inc. (Tokyo, Japan) after quarantine and reared for over 3 years in a controlled animal area. The monkeys at 6-8 years of age that had not been administered any drugs for at least one week before the experiment, were used in this study. Diets were freely accessible for rats and supplied once daily for monkeys. Water was given ad libitum throughout the experiments.
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Construction of Recombinant Rat Salivary Amylase (rAmy1).
After the isolation of the rat parotid gland from SD rats under diethyl ether inhalation, rat parotid RNA was extracted by TRIzol reagent (Life Technologies Corp., Carlsbad, CA, USA) and rAmy1 cDNA was obtained by a reverse transcriptional-polymerase chain reaction (Invitrogen SuperScriptIII One
Step RT-PCR system, Life Technologies Corp.) using the forward primer 5'-ggg gac aag ttt gta caa aaa agc agg ctt cac cAT GAG AGA ATA CTG CCA ACA TCA TAG C-3', and the reverse primer 5'-ggg gac cac ttt gta caa gaa agc tgg gtc GAT TTT TGA CTC TAC ATG GAT TGC AAT G-3'. Amplified rAmy1 was purified by an Invitrogen PureLink PCR media was purified by His-tag affinity purification using Ni-NTA agarose to obtain the recombinant rat salivary amylase (0.71 mg protein/ml, 6 × histidine and V5 epitope fused to the C-terminus of rat salivary amylase).
Immunoprecipitation (IP).
The rat salivary amylase solution (10.7 µg protein/ml in phosphate buffered saline This article has not been copyedited and formatted. The final version may differ from this version. (PBS, pH7.4)) and rat plasma (pooled, n = 15) were mixed with either control or amylase antibody solutions (1 mg protein/ml), using a ratio of 5/1 (v/v) and incubated at 4°C overnight. Then, protein G plus agarose (SantaCruz Technologies, Inc., Santa Cruz, CA, USA) was added to the sample, using a ratio of 3/4 (v/v, protein G agarose/plasma or rat salivary amylase solution) and incubated at 4°C for more than 1 hour. The sample was centrifuged at approximately 160 g for 1 minute at 4°C and the supernatant was used as IP-plasma or IP-amylase for amylase activity measurement and ultrafiltration.
Protein Binding Assay of CS-1036 by Ultrafiltration.
For in vitro plasma protein binding, blood was taken from the abdominal aorta of 11 samples were drawn prior to dosing and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, and 48 hours after the dose. Then, blood samples were centrifuged to yield plasma.
Urine samples were collected continuously up to 48 hours after the dose. The total volume of urine at each period was recorded. The plasma and urine samples were stored at -20°C.
Determination of CS-1036 Concentration by LC-MS/MS.
CS-1036 concentrations in the plasma, in vitro samples, their filtered samples and tissue samples were determined in accordance with a reported quantification method using LC-MS/MS with minor modifications (Honda et al., 2013) .
Measurement of Amylase Activity.
The amylase activities in rat plasma, recombinant amylase and their IP-samples diluted with PBS were measured using an amylase activity measurement kit (Sekisui Medical Co., Ltd., Tokyo, Japan). The absorbance of the sample at 660 nm was normalized by that at 405 nm and the amylase activity was calculated from the mean value of the duplicate (VERSAmax, Molecular Devices, LLC., Sunnyvale, CA, USA). The enzyme calibrator plus (Sysmex Corp., Kobe, Hyogo, Japan) was used as the reference standard to adjust the amylase activity of recombinant rat salivary amylase. The specific activity of recombinant rat salivary amylase (U/mg protein) was determined and the amylase concentration in rat plasma (mg or μ g protein/ml) was subsequently calculated.
PK Analysis.
The PK parameters of CS-1036 in the plasma were calculated using WinNonlin Professional (Version 4.0.1 or 5.2; Pharsight Corp., Mountain View, CA, USA) based on a non-compartmental method in the same way as previously reported (Honda et al., 2013) .
In humans, the urinary excretion ratio (Fe) was determined by multiplying the urinary concentration, urine volume and by 100, and then normalized by the dose. The CL R was determined by dividing the amount of drug excreted in urine up to 48 hours after the dose by the plasma concentration versus time curve (AUC) up to 48 hours.
Data Analysis.
The fu and the protein binding (%) was calculated by the following equations 1 and 2, respectively. 
where Cb is the bound concentration and B max is defined by multiplying the number of CS-1036 binding sites in the protein by the binding protein concentration.
Using the estimated K D and B max , the fu of CS-1036 in rat and monkey PK studies (Honda et al., 2013) was calculated by the following equation 5, which was converted from equation 4.
The reported area under the AUC up to the last quantifiable time (AUC last ) of CS-1036 in rats and monkeys (Honda et al., 2013) was normalized by the dose. AUC/dose was compared among the dose levels by a Siegel-Tukey test. P values of less than 0.05 were considered to be statistically significant. This article has not been copyedited and formatted. The final version may differ from this version. 
Results
In Vitro Plasma Protein Binding of CS-1036 in Rats, Monkeys and Humans.
The plasma protein binding in rats, monkey and humans was evaluated by ultrafiltration. The fu of CS-1036 in rat and monkey plasma in the nominal concentration range of 22.7-11300 nM increased in a concentration-dependent manner ( Figs. 2A and B) , but over the same concentration range, the fu in humans (>0.898±0.032) showed no concentration dependency (Fig. 2C) . The plasma protein binding of CS-1036 in rats and monkeys was well explained by the Langmuir model. As shown in Table 1 , the K D of CS-1036 in monkey plasma (27.2 nM) was approximately 3-fold higher than that in rat plasma (8.95 nM). The B max of CS-1036 in monkey plasma (22.1 nM) was approximately half of that in rat plasma (52.8 nM). (Kawase et al., 2013) . Therefore, the binding proteins of CS-1036 in plasma were considered to be minor proteins. The serum amylase, which is potentially the same as the pharmacological target protein of CS-1036 and tested clinically for serum chemistry (Ranson, 1997) , was considered as a possible candidate for the binding protein of CS-1036. For the evaluation of the target binding protein of CS-1036 in the plasma, the recombinant rat salivary amylase was constructed and used with an adjustment of the amylase activity almost the same as that in rat plasma This (Figs. 3C and D, respectively) . The amylase activities of human salivary and pancreatic amylase in this evaluation were set much higher (≥10-fold) than those in in vivo serum amylase (Takasaka et al., 2003) .
CS-1036 Binding to
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Effects of IP on CS-1036 Binding.
After the IP of amylase in rat plasma by anti-human salivary amylase antibody, the cross reactivity of the amylase antibody was confirmed by the decrease of the amylase activities in rat IP-plasma (<20% of the control) (Fig. 4C) . In a similar manner, the plasma protein binding of CS-1036 in rat amylase IP-plasma decreased to 22.2%-36.3% of rat control IP-plasma (Fig. 4A) . The enzyme activity of rat amylase IP-amylase was almost completely depressed to 2.9% of rat control IP-amylase (Fig. 4C) . The protein binding of CS-1036 in rat amylase IP-amylase decreased to 6.4%-10.4% of rat control IP-amylase (Fig. 4B) . Thus, the enzyme activity in rat amylase IP-and control IP-plasma showed a correlation with the fu of CS-1036 in rat amylase IP and control IP salivary amylase. This The plasma concentration-time profiles and PK parameters of CS-1036 in healthy male subjects after oral administration are shown in Fig. 5 and Table 2 , respectively. The time to reach maximum plasma concentration (t max ) was observed at 1.25-1.75 hours after administration. The maximum plasma concentration (C max ) and AUC up to infinity (AUC 0-inf ) of CS-1036 increased in an almost dose-proportional manner over the dose range of 5-160 mg. The Fe was <1%, which was similar to the F oral in monkeys (Honda et al., 2013) . The t 1/2 (3.7-7.9 hours) was shorter than those in intravenous administration ≥ 3 mg/kg (23.6-30.0 hours) and in oral administration at 10 mg/kg (12.6-18.3 hours) in rats and monkeys (Honda et al., 2013) , which were determined with sufficient time points at the elimination phases. Less than 1% of the dose was excreted into urine up to 48 hours after oral administration, and the CL R of CS-1036 was relatively constant (82.3-119.1 ml/min), regardless of the dose.
Estimation of the fu in Rat and Monkey PK study.
The fu for the plasma concentrations of CS-1036 in rats and monkeys, which was previously reported (Honda et al., 2013) , was calculated by equation 5 using the in vitro K D and B max of CS-1036 in plasma (Table 1) . After intravenous administration of CS-1036, the fu for CS-1036 was calculated to be ≥ 0.88 up to 2 hours after the dose for rats (Fig. 6A ) and up to 4 hours after the dose for monkeys for all doses (Fig. 6B ). It remarkable dose-dependency especially in rats (0.2 to 0.9 from 0.3 to 10 mg/kg) compared to that in monkeys (0.6 to 0.9 from 0.3 to 10 mg/kg), then decreased with time, and finally became almost constant near the end of the elimination phase (ca. 0.15 for rats and 0.56 for monkeys), being similar values to those after intravenous administration (Fig. 7) . The B max in rats and monkeys was between the C max at 0.3 and 1 mg/kg for both animals, and then the fu at the t max resulted in wide ranges for oral administration. In addition, the higher K D and the lower B max in monkeys compared to those in rats were considered to result in smaller changes in the fu of CS-1036 in monkeys (0.6-0.9) compared to those in rats (0.2-0.9). At 0.3 mg/kg after oral administration to rats, the plasma concentration of CS-1036 was lower than the B max in the overall observed period, and then the fu was almost constant (ca. 0.2).
This article has not been copyedited and formatted. The final version may differ from this version. On the other hand, CS-1036 did not bind to rat albumin, and showed a lower B max than the plasma concentrations of albumin (ca 350 μ M) and AGP (ca 7 μ M) in rats (Kawase et al., 2013) . As a candidate for CS-1036 binding protein, serum amylase, which is known as a biomarker for pancreatic function (Ranson, 1997) and potentially the same as the pharmacological target protein of CS-1036, was evaluated. Rats exhibit salivary (Amy1) and pancreatic amylase (Amy2-1 and Amy2-2) (Sugino, 2007) , and the former was reported as a major subtype in rat plasma (Takeuchi et al., 1975; Tomasik et al., 1995) .
Then, the concentration-dependent binding to recombinant rat salivary amylase was observed with a similar K D (5.64 nM) to those obtained from rat plasma (8.95 nM). In the IP of rat amylase, anti-human salivary amylase antibody showed suppressive effects on the plasma amylase activity and protein binding of CS-1036 in rat plasma, and rat salivary amylase. From these results, CS-1036 binding protein in rat plasma was identified as salivary amylase, which is a novel finding to show that drugs bind to serum amylase. Alpha-glycosidase inhibitor, acarbose, which also exhibits α -amylase inhibitory effects (Hiele et al., 1992) , showed relatively long t 1/2 in rats and dogs and humans (23-24 hours) with a concentration-dependent plasma protein binding in rats and dogs (Ahr et al., 1989) , suggesting that serum amylase may contribute to the plasma This article has not been copyedited and formatted. The final version may differ from this version. Human salivary and pancreatic amylases exhibit relatively high homologies with rat amylases (>80%), and both amylases are almost equally secreted into human plasma (Gumucio et al., 1988; Mashige et al., 1989) . Indeed, CS-1036 also showed a concentration-dependent and saturable plasma protein binding to human pancreatic and salivary amylase with the K D of 8.74 and 4.92 nM, respectively, which were similar to that in rat plasma, and rat salivary amylase. However, the concentration-dependent and saturable plasma protein binding of CS-1036 was not observed in human plasma. The amylase activity in human plasma was reported to be 40-162 U/L (Takasaka et al., 2003) , and that in rats was 10-30-fold higher (1220 U/L) in the present study, indicating that the B max is much higher in rats than that in humans. Thus, in rats and monkeys, since the plasma protein binding of CS-1036 was concentration-dependent and saturable, the t 1/2 became longer (18.4-30.0 hours for ≥ 1 mg/kg i.v.) (Honda et al., 2013) . While, in humans, the plasma protein binding was effectively saturated and constant, the t 1/2 became shorter (3.7-7.9 hours). In the case of dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, which also binds to the pharmacological target protein and exhibits a concentration-dependent and saturable plasma protein binding, the model-based simulation suggests that the higher B max lead to a longer t 1/2 of the Ct (Retlich et al., 2009 ).
CS-1036 is a small and highly hydrophilic molecule with a trisaccharide structure (molecular weight; 441.43), and was excreted into urine (Honda et al., 2013) . As anticipated, given that the plasma protein binding appears to be saturated in humans at the doses studied, the CL R of CS-1036 in humans was almost constant and comparable to GFR (Davies and Morris, 1993) , indicating that CS-1036 is eliminated mainly by should alter the CL R and then CL in a dose-dependent manner although the CL in rats and monkeys was almost constant at doses of 0.3-10 mg/kg for intravenous administration (Honda et al., 2013) .
To clarify the discrepancy why the dose-dependent CL was not observed even with the concentration-dependent and saturable plasma protein binding in rats and monkeys, the time-dependent changes of the fu were simulated for rats and monkeys. For intravenous administration, the fu was close to 1 up to 2 hours for rats and 4 hours for monkeys (Fig.   6 ), and AUC 0-2h for rats and AUC 0-4h for monkeys corresponding to >85% of total AUC for rats and 90% for monkeys, respectively. Therefore, the CL in both animals was thought to be constant in this dose range. On the other hand, for oral administration, the fu changed dramatically with the doses (Fig. 7) because a low F oral of CS-1036 in rats and monkeys (1%-2%) leads to the much lower plasma concentrations (C max : 36.7-646 nM for rats and 11.8-344 nM for monkeys at 0.3-10 mg/kg) than those after intravenous administration (Honda et al., 2013) . Therefore, for oral administration, the CL is considered to increase with the dose in proportion with the increase of the fu at higher doses. Indeed, the AUC/dose, which is inversely correlated with the CL, at low doses such as 0.3 mg/kg for oral administration in rats was higher than that in higher doses ( case of insulin-like growth factor-1 (IGF-1), which also exhibited a concentration-dependent and saturable plasma protein binding, the CL for total IGF-1 increased with the dose, and then the AUC/dose was decreased with the dose (Mizuno et al., 2001 ). On the other hand, for oral administration in monkeys, the higher AUC/dose at the lowest dose was not observed, but the AUC/dose of CS-1036 increased with the dose. This might be due to low exposures of CS-1036 close to the lower limit of quantification at lower doses in the PK study for oral administration, and there were less time points of which concentrations were determined at the lower doses compared to those at higher doses in monkeys.
In conclusion, CS-1036 showed a concentration-dependent and saturable plasma protein binding in animals, but apparently not in humans. Alpha-amylase in the plasma was identified as the target plasma binding protein, and the species difference of the serum amylase level (B max ) is suggested to influence the elimination rate of CS-1036.
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Fig. 6
Time profiles of the calculated fu of CS-1036 after intravenous administration of CS-1036 to rats (A) and monkeys (B). The fu was calculated from the mean plasma concentrations, which was cited from the previous report (Honda et al., 2013) .
Fig. 7
Time profiles of the calculated fu of CS-1036 after oral administration of CS-1036 to rats (A) and monkeys (B). The fu was calculated from the mean plasma concentrations, which was cited from the previous report (Honda et al., 2013) .
Fig. 8
Relationships between dose-normalized AUC and dose after intravenous (A) and oral administration (B) to rats and monkeys. The reported AUC last (Honda et al., 2013) was normalized by the dose. The data are expressed as the mean ± S.E. (n = 3 or 4). *: P < 0.05
